FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions of Beh çet ' s Disease

PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news